Explore. Learn. Join the conversation.

Working Group on New TB Drugs

Stop TB Partnership

Targets

« Return to Targets Overview

Contact Info

Sophie Lagrange sophie.lagrange@sanofi-aventis.com

FabG1

Last Updated: 2-Nov-2011

Target Description

EC number
EC 1.1.1.100
Genbank accession
NP_215999 / P0A5Y4
Rv number
Rv1483


Research Investigator(s)
Sanofi-aventis, Toulouse center

Has the target been validated? How?

Validated by:
Genetically (in vitro or in vivo)
PubMed References
J. Bacteriology  2007  vol189  10  3721-3728Microbiology  2002  148  951-960  

Reagent Description

Recombinant Protein Name / Gene ID Soluble? Truncated? Mutant? PubMed References
3-oxoacyl-[acyl-carrier protein] reductase / 886551 Yes No

Assay Description

Assay Name Readout Format PubMed References
NADPH consumption assessment Fluorescence 96-well plate
NADPH-dependent tetrazolium reduction Absorbance 96-well plate

Compounds for Screening or Lead Optimization

Library Name/Indentifier Total # of Compounds Screened HTS Cut Off (ie. 40 um) # of Hits # of Leads PubMed References
Sanofi aventis library XXXXk 574000 10µM 680 0
Rational design/fragment-based screening 0 0 0

Hits or Leads

Counter-Screen Assay (Target or Cell Based)

enzymatic assay without the enzyme activity on TB growth screened 300 number of hits 57 0 number of leads 0

Narrative Description